Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan

A technology of ceftriaxone sodium and ceftriaxone sodium, which is applied in the field of biomedicine, can solve the problems of uncontrollable dosage, unclear biological toxicity, and high cost, and achieve the effect of reducing clinical diagnosis procedures, reducing burden and pain, and simple equipment

Inactive Publication Date: 2011-09-28
TONGJI UNIV
0 Cites 5 Cited by

AI-Extracted Technical Summary

Problems solved by technology

However, nanomaterials, heavy metal materials, and other drugs have disadvantages such as high cost, uncontrollable dosage, and unclear biological toxicity. In the process of using drugs, adding non-biological...
View more

Abstract

The invention relates to a synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan. According to the method, a natural nontoxic macromolecular substance chitosan is added to the commercial ceftriaxone sodium to play a synergetic effect on the bacterial inhibition of the ceftriaxone sodium. Compared with the prior art, excellent synergetic bacterial inhibition of the ceftriaxone sodium is achieved by the chitosan, thus greatly reducing the dosage of the original ceftriaxone sodium, and achieving a better bacterial inhibition effect by a lower drug concentration.

Application Domain

Antibacterial agentsOrganic active ingredients

Technology Topic

Macromolecular SubstancesChemistry +4

Image

  • Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan
  • Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan
  • Synergetic method for bacterial inhibition of ceftriaxone sodium by chitosan

Examples

  • Experimental program(5)
  • Effect test(1)

Example Embodiment

[0030] Example 1
[0031] (1) Preparation of chitosan acetic acid solution: Weigh 0.01g of chitosan and dissolve in 10ml of 2% acetic acid solution, heat and stir until fully dissolved, showing a colorless and transparent viscous solution with a concentration of 1mg/ml. Add commercially available ceftriaxone sodium for injection (1g) into 10ml sterile water to prepare a 100mg/ml medicinal solution for use.
[0032] (2) Under ultrasonic stirring, mix the chitosan acetic acid solution with the commercially available ceftriaxone sodium solution for injection at a mass ratio of 1:0.5, and stir for 30 minutes to fully mix the two to achieve the antibacterial performance of ceftriaxone sodium. Perform chitosan synergy.
[0033] (3) First, Escherichia coli (BH21) must be activated in the frozen state to restore its activity. Add the Escherichia coli strain to the LB liquid medium with 1% of the inoculum, and cultivate it overnight at 37.5°C in a constant temperature shaking water tank recovery. Dilute the cultured E. coli broth with LB liquid medium to reach a concentration of 1.0×10 7 cfu is ready to use.
[0034] (4) Use the flat-plate confrontation growth method to test. At the four corners 30 mm from the center of the LB solid medium plate, use a hole puncher with a hole diameter of 8 mm to open holes, and inject 100 μl of the liquid medicine into the holes, and let the liquid medicine completely enter the medium at 37.5°C overnight. Take 800 μl of the Escherichia coli prepared in the second step and evenly spread it on the medium prepared in the previous step. Incubate at 37.5°C for 24 hours and observe the experimental results.
[0035] From figure 2 In 3, it can be seen that the mixed solution of chitosan and ceftriaxone sodium has achieved a good synergistic and antibacterial effect, far exceeding the effect of using the two alone.
[0036] (5) Use the mixed bacteria method to test. Mix 400 μl of the medicinal solution with 800 μl of E. coli prepared in the second step, and act for 30 minutes, and then take 800 μl of the mixed solution and evenly spread on the plate. Incubate at 37.5°C for 24 hours and observe the experimental results.
[0037] From figure 2 In 4, it can be seen that the mixed solution of chitosan and ceftriaxone sodium has achieved a good synergistic and antibacterial effect, which far exceeds the effect of using the two alone.

Example Embodiment

[0038] Example 2
[0039] Under ultrasonic stirring, the chitosan acetic acid solution was mixed with the commercially available ceftriaxone sodium solution for injection at a mass ratio of 1:2, and stirred for 30 minutes to fully mix the two to achieve the antibacterial performance of ceftriaxone sodium. Sugar synergistically. From the change in the diameter of the inhibition zone in Table 1, it can be seen that good synergistic antibacterial performance is also achieved, which exceeds the efficacy of the two used alone.

Example Embodiment

[0040] Example 3
[0041] Under ultrasonic stirring, the chitosan acetic acid solution was mixed with the commercially available ceftriaxone sodium solution for injection at a mass ratio of 1:10, and stirred for 30 minutes to fully mix the two to achieve the antibacterial properties of ceftriaxone sodium. Sugar synergistically. From the change in the diameter of the inhibition zone in Table 1, it can be seen that good synergistic antibacterial performance is also achieved, which exceeds the efficacy of the two used alone.

PUM

PropertyMeasurementUnit
Concentration0.5 ~ 5.0mg/ml
Concentration1.0mg/ml

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.

Similar technology patents

Bionic enzymatic hydrolysate for scorpion and application thereof

Owner:北京凯瑞创新医药科技有限公司

Sterilizing gel

Owner:GUANGZHOU PUIS PHARMA FACTORY

Classification and recommendation of technical efficacy words

  • Improve curative effect
  • lower dose

New formulation oxaliplatin liposome

InactiveCN1775216AImprove poor oral absorptionImprove curative effect
Owner:胡才忠

Recombinant human granulocyte-macrophage colony stimulating factor gel

InactiveCN1435258AThe mechanism of action is clearlower dose
Owner:HARBIN PHARMA GROUP TECH CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products